Oslo, Norway, April 10, 2025 - Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, has today published its Annual Report for 2024, which was approved by the board of directors on April 9, 2024.

2024 marked a defining year for Lytix, with significant clinical progress and strategic milestones that further de-risk and validate the company's unique immuno-oncology platform.

"2024 has been a transformative year for Lytix Biopharma," said Øystein Rekdal, CEO of Lytix Biopharma. "We've seen continued strong clinical progress, notably through our partnership with Verrica, where LTX-315 achieved a 97% calculated objective response rate in a Phase II study for basal cell carcinoma. This brings us closer to Phase III and, ultimately, commercialization. With an expanded pipeline, robust scientific validation, and strengthened financial position, Lytix is well positioned as we move into 2025, a year where we expect to reach significant milestones that bring us closer to delivering our immunotherapies to patients."

The Annual Report for 2024 is attached to this notice and is also available on the company's website, www.lytixbiopharma.com, under Investors.

For further information, please contact:

Gjest Breistein, CFO

E-mail: gjest.breistein@lytixbiopharma.com

Phone: +47 952 60 512

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.